Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Drugmaker stocks lead sector with healthy dividends
03:50pm, Friday, 23'rd Sep 2022
CNBC's Bertha Coombs reports on health care stocks.
Health care stocks with dividend yields to weather through market turmoil
09:19am, Friday, 23'rd Sep 2022
The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields.
Organon: What Is The Recipe?
06:18pm, Wednesday, 31'st Aug 2022
Organon has seen a real struggle in its first year on its own as a publicly listed business. Lack of growth was anticipated, yet the extent of margin pressure has been unexpected.
New Strong Sell Stocks for August 8th
08:17am, Monday, 08'th Aug 2022
COWN, AUD, and OGN have been added to the Zacks Rank #5 (Strong Sell) List on August 8, 2022.
Organon & Co. (OGN) CEO Kevin Ali on Q2 2022 Results - Earnings Call Transcript
01:04pm, Thursday, 04'th Aug 2022
Organon & Co. (NYSE:OGN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
07:30am, Thursday, 21'st Jul 2022
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #organon--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company's webcast and call scheduled for 8:30 a.m. EDT.
Organon Vs. Viatris: Who Is The Clear Winner?
09:23pm, Sunday, 19'th Jun 2022
Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a ye
Organon: Maximum Optimism
01:04pm, Thursday, 28'th Apr 2022
Biosimilar sales were $118 million in Q4 2021, up 14.6% from Q4 2020. Organon's dividend yield is around 3.5%, which is one of the largest in the pharmaceutical industry.
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
01:32pm, Monday, 25'th Apr 2022
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
10:20am, Friday, 15'th Apr 2022 Zacks Investment Research
Sector ETF report for XPH
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
01:33pm, Thursday, 31'st Mar 2022
Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating
3 of the Best Value Stocks to Buy Heading Into April
03:07pm, Wednesday, 30'th Mar 2022 The Motley Fool
With these shares at modest valuations, you can score some cheap long-term investments.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
10:20am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for XPH
Organon supports fight against heart disease in Filipinos
12:17pm, Thursday, 10'th Mar 2022 BusinessMirror
Do you know your lipid profile? High cholesterol usually has no signs or symptoms. The only way to…
